Clinical Trial: A Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023614) titled 'A Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy' on June 09.

Brief Summary: FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Non-obstructive Hypertrophic Cardiomyopathy

Intervention: DRUG: Ninerafaxstat 200mg MR

Ninerafaxstat 200mg Modifie...